Copyright © All rights reserved.  Terms of use | Privacy policy

www.bioinventia.com

More than 250 million people have already benefited from Biotech Medicines and vaccines developed through biotechnology. A survey by the Pharmaceutical Research and Manufacturers of America (PhRMA) a couple years ago - identifies 371 more biotechnology medicines in the pipeline. Nearly 200 diseases are being targeted by this research conducted by 144 companies and the National Cancer Institute. These new medicines – all of which are in human clinical trials or are awaiting FDA approval –include 178 new medicines for cancer, 47 for infectious diseases, 26 for autoimmune diseases, 22 for neurologic disorders, and 21 for HIV/AIDS and related conditions. Approved biotech medicines already treat or help prevent heart attacks, stroke, multiple sclerosis, leukemia, hepatitis, rheumatoid arthritis, breast cancer, diabetes, congestive heart failure, lymphoma, kidney cancer, cystic fibrosis and other diseases.Bioinventia are capable to arrange licensing Agreements with the Manufacturers for Biotech Medicines with complete Regulatory requirements for Pakistan, Middle East & CIS Markets.